A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00550446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double Blind, Placebo Controlled Active Comparator, Multicenter Study To Compare 5 Dose Regimens Of CP- 690,550 And Adalimumab Versus Placebo, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis
Study identification
- NCT ID
- NCT00550446
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 386 participants
Conditions and interventions
Conditions
Interventions
- Adalimumab Drug
- CP-690,550 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Dec 31, 2008
- Completion
- Dec 31, 2008
- Last update posted
- Jan 2, 2013
2007 – 2009
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mesa | Arizona | 85208 | — |
| Pfizer Investigational Site | Little Rock | Arkansas | 72205 | — |
| Pfizer Investigational Site | Northridge | California | 91325 | — |
| Pfizer Investigational Site | Palo Alto | California | 94304 | — |
| Pfizer Investigational Site | Stanford | California | 94305 | — |
| Pfizer Investigational Site | Tarzana | California | 91356 | — |
| Pfizer Investigational Site | Upland | California | 91786 | — |
| Pfizer Investigational Site | Orlando | Florida | 32804 | — |
| Pfizer Investigational Site | Tampa | Florida | 33614 | — |
| Pfizer Investigational Site | Morton Grove | Illinois | 60053 | — |
| Pfizer Investigational Site | Rockford | Illinois | 61107 | — |
| Pfizer Investigational Site | Cedar Rapids | Iowa | 52401-2112 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67203 | — |
| Pfizer Investigational Site | Wichita | Kansas | 67208 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70115 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28601 | — |
| Pfizer Investigational Site | Hickory | North Carolina | 28602 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45408 | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Knoxville | Tennessee | 37909-1600 | — |
| Pfizer Investigational Site | Dallas | Texas | 75235 | — |
| Pfizer Investigational Site | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00550446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 2, 2013 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00550446 live on ClinicalTrials.gov.